EPISODE · Nov 10, 2025 · 30 MIN
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
from Squawk Box Europe Express
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal’s lack of guarantees on healthcare. Meanwhile, China will resume exports of Nexperia chips following a row with the Dutch government, potentially giving a boost to the autos industry which had been hit by the supply shock. In pharma news, the battle between Pfizer and Novo Nordisk for weight-loss biotech Metsera has ended, with the Danish conglomerate losing out in the $10 billion deal.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What this episode covers
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal’s lack of guarantees on healthcare. Meanwhile, China will resume exports of Nexperia chips following a row with the Dutch government, potentially giving a boost to the autos industry which had been hit by the supply shock. In pharma news, the battle between Pfizer and Novo Nordisk for weight-loss biotech Metsera has ended, with the Danish conglomerate losing out in the $10 billion deal. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
NOW PLAYING
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
No transcript for this episode yet
Similar Episodes
Sep 28, 2025 ·38m
Sep 20, 2025 ·49m
Sep 13, 2025 ·41m
Sep 7, 2025 ·41m
Sep 1, 2025 ·49m
Aug 25, 2025 ·45m